151 related articles for article (PubMed ID: 20010870)
1. Copine-III interacts with ErbB2 and promotes tumor cell migration.
Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
[TBL] [Abstract][Full Text] [Related]
2. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J
Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186
[TBL] [Abstract][Full Text] [Related]
3. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
[TBL] [Abstract][Full Text] [Related]
7. Heregulinbeta activates store-operated Ca2+ channels through c-erbB2 receptor level-dependent pathway in human breast cancer cells.
Liao JY; Li LL; Wei Q; Yue JC
Arch Biochem Biophys; 2007 Feb; 458(2):244-52. PubMed ID: 17214955
[TBL] [Abstract][Full Text] [Related]
8. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
9. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling.
Yong HY; Kim IY; Kim JS; Moon A
Int J Oncol; 2010 Feb; 36(2):501-7. PubMed ID: 20043086
[TBL] [Abstract][Full Text] [Related]
10. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
11. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
[TBL] [Abstract][Full Text] [Related]
13. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
14. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.
Cicenas J; Urban P; Küng W; Vuaroqueaux V; Labuhn M; Wight E; Eppenberger U; Eppenberger-Castori S
Eur J Cancer; 2006 Mar; 42(5):636-45. PubMed ID: 16414259
[TBL] [Abstract][Full Text] [Related]
16. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
Mukherji M; Brill LM; Ficarro SB; Hampton GM; Schultz PG
Biochemistry; 2006 Dec; 45(51):15529-40. PubMed ID: 17176074
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
Kim KK; Lee JJ; Yang Y; You KH; Lee JH
Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
[TBL] [Abstract][Full Text] [Related]
20. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]